摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-四唑-1-基-苄胺 | 449756-94-9

中文名称
2-四唑-1-基-苄胺
中文别名
——
英文名称
2-Tetrazol-1-yl-benzylamine
英文别名
{[2-(1H-tetrazol-1-yl)phenyl]methyl}amine;[2-(1H-tetrazol-1-yl)benzyl]amine;2-(1-Tetrazolyl)benzylamine;[2-(tetrazol-1-yl)phenyl]methanamine
2-四唑-1-基-苄胺化学式
CAS
449756-94-9
化学式
C8H9N5
mdl
MFCD09842784
分子量
175.193
InChiKey
KAPGCSIVXSTJOS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.1
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.125
  • 拓扑面积:
    69.6
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Discovery and Evaluation of Potent P1 Aryl Heterocycle-Based Thrombin Inhibitors
    摘要:
    In an effort to discover potent, clinically useful thrombin inhibitors, a rapid analogue synthetic approach was used to explore the P-1 region. Various benzylamines were coupled to a pyridine/pyrazinone P-2-P-3 template. One compound with an o-thiadiazole benzylic substitution was found to have a thrombin K-i of 0.84 nM. A study of ortho-substituted five-membered-ring heterocycles was undertaken and subsequently demonstrated that the o-triazole and tetrazole rings were optimal. Combination of these potent P-1 aryl heterocycles with a variety of P-2-P-3 groups produced a compound with an extraordinary thrombin inhibitory activity of 1.4 pM. It is hoped that this potency enhancement in P-1 will allow for more diversification in the P-2-P-3 region to ultimately address additional pharmacological concerns.
    DOI:
    10.1021/jm030303e
  • 作为产物:
    描述:
    2-(1H-Tetrazol-1-YL)benzonitrile 作用下, 以 为溶剂, 反应 2.0h, 以to obtain the desired product (80 mg)的产率得到2-四唑-1-基-苄胺
    参考文献:
    名称:
    1-6-Substituted (3R,6R)-3-(2,3-Dihydro-1H-Inden-2-Yl)-2,5-Piperazinedione Derivatives as Oxytocin Receptor Antagonists For the Treatment of Preterm Labour, Dysmenorrhea and Endometriosis
    摘要:
    本发明涉及化合物S,其化学式为(I)。
    公开号:
    US20080242666A1
点击查看最新优质反应信息

文献信息

  • Thrombin inhibitors
    申请人:——
    公开号:US20030158218A1
    公开(公告)日:2003-08-21
    Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: 1 wherein R 1 is, for example, hydrogen, Cl, or cyano, and R 2 is, for example, hydrogen, 2
    本发明的化合物在抑制凝血酶及相关血栓闭塞方面具有以下结构的有用: 1 其中R 1 例如是氢、基,而R 2 例如是氢、 2
  • [EN] NEW 5,6-DIHYDROPYRIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN<br/>[FR] NOUVEAUX COMPOSES DE 5,6-DIHYDROPYRIN-2-ONE UTILES EN TANT QU'INHIBITEURS DE THROMBINE
    申请人:ASTRAZENECA AB
    公开号:WO2005058826A1
    公开(公告)日:2005-06-30
    There is provided a compound of formula (I) wherein R1, R2a, R2b, R3a, R3b, R4, R5, R6, A, G and L have meanings given in the description, which compounds are useful as, or are useful as prodrugs of, competetive inhibitors of trypsin-like proteases, such as trombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is beneficial (e,g. conditions, such as thrombo-embolisms, where inhibition of trombin is required or desired, and/or conditions wherea anticoagulant thererapy is indicated).
    提供了一个式(I)的化合物,其中R1、R2a、R2b、R3a、R3b、R4、R5、R6、A、G和L的含义如描述中所给,这些化合物可用作或可用作胰蛋白酶类竞争性抑制剂的前体药物,例如血栓素,因此特别适用于治疗需要抑制血栓素有益的疾病(例如需要或希望抑制血栓素的血栓栓塞等疾病,以及抗凝治疗适用的疾病)。
  • [EN] NEW PYRIDIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN<br/>[FR] NOUVEAUX COMPOSES DE PYRIDIN-2-ONE UTILISABLES EN TANT QU'INHIBITEURS DE THROMBINE
    申请人:ASTRAZENECA AB
    公开号:WO2005075424A1
    公开(公告)日:2005-08-18
    There is provided a compound of formula I, wherein the dashed line, R1, R2, R3a, R3b, A, D, E, G and L have meanings given in the description, which compounds are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is beneficial (e.g. conditions, such as thrombo-embolisms, where inhibition of thrombin is required or desired, and/or conditions where anticoagulant therapy is indicated).
    提供了一个式I的化合物,其中虚线、R1、R2、R3a、R3b、A、D、E、G和L的含义如描述中所示,这些化合物可用作竞争性蛋白酶抑制剂,如凝血酶,或者可用作其前药,特别适用于需要抑制凝血酶有益的情况的治疗(例如需要或希望抑制凝血酶的情况,如血栓栓塞等情况,以及需要抗凝治疗的情况)。
  • [EN] THROMBIN INHIBITORS<br/>[FR] INHIBITEURS DE LA THROMBINE
    申请人:MERCK & CO INC
    公开号:WO2002064140A1
    公开(公告)日:2002-08-22
    Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: or a pharmaceutically acceptable salt thereof, wherein R2 is R3 is selected from the group consisting of 1) hydrogen, 2) halogen, 3) C 1-4 alkyl, 4) C 3-7 cycloalkyl, 5) CF3, 6) OCF3, 7) C 1-4 alkoxy, and 8) cyano; and R12 is a 5-membered heteroaryl ring having 2, 3, or 4 heteroatoms, provided that at least 1 heteroatom is N, and at most 1 of the heteroatoms is S, said ring being unsubstituted or substituted, at any one ring atom, with CH3.
    本发明的化合物在抑制凝血酶和相关的血栓闭塞方面有用,其结构如下:或其药学上可接受的盐,其中R2和R3选自以下组:1)氢,2)卤素,3)C 1-4 烷基,4)C 3-7 环烷基,5)CF3,6)O ,7)C 1-4 醇基,8)基;R12是一个具有2、3或4个杂原子的5元杂环芳基环,其中至少1个杂原子是N,至多1个杂原子是S,所述环未取代或在任何一个环原子上用CH3取代。
  • 5,6-Dihydropyrin-2-one compounds useful as inhibitors of thrombin
    申请人:Berggren Kristina
    公开号:US20070099962A1
    公开(公告)日:2007-05-03
    There is provided a compound of formula (I) wherein R 1 , R 2a , R 2b , R 3a , R 3b , R 4 , R 5 , R 6 , A, G and L have meanings given in the description, which compounds are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as trombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is beneficial (e.g. conditions, such as thrombo-embolisms, where inhibition of trombin is required or desired, and/or conditions whereas anticoagulant therapy is indicated).
    提供了一个化合物的公式(I),其中R1,R2a,R2b,R3a,R3b,R4,R5,R6,A,G和L的含义如描述中所给,这些化合物可用作具有竞争性的胰蛋白酶蛋白酶抑制剂或其前药,例如血栓素,因此特别适用于治疗抑制血栓素有益的疾病(例如需要或希望抑制血栓素的血栓栓塞等疾病,以及需要抗凝治疗的疾病)。
查看更多